Who Paid My Doc
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
Research payments
$40,547,701
Through program year 2025, $40,547,701 in research payments was reported against A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease, across 759 payments, paid by Vertex Pharmaceuticals Incorporated.
- Paid by
- Vertex Pharmaceuticals Incorporated
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $13,800,574 | 222 |
| 2024 | Research | $16,283,601 | 235 |
| 2023 | Research | $8,088,537 | 184 |
| 2022 | Research | $2,374,988 | 118 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Hassan Hachem Phoenix, AZ Named on 4 payments
- Elizabeth Nguyen Atlanta, GA Named on 4 payments
- Leroy Herbert New York, NY Named on 4 payments
- Edgard Vera Tapia Victorville, CA Named on 4 payments
- Mohamed Atta Baltimore, MD Named on 3 payments
- Rajeev Chauhan Columbus, GA Named on 3 payments
- Sreedhar Mandayam Houston, TX Named on 3 payments
- Manuel Montero New Bern, NC Named on 3 payments
- Jennifer Odren Saint Clair Shores, MI Named on 3 payments
- Charmaine Emelife East Point, GA Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.